The sulfonylurea controversy: more questions from the heart

Department of Medicine, Mayo Clinic, Mayo Foundation, Rochester, Minnesota 55905, USA.

Myocardial ischemia and infarction are associated with substantially increased morbidity and mortality among patients with diabetes mellitus. Although many factors contribute to the increased morbidity and mortality, in patients with non-insulin-dependent (type II) diabetes mellitus, one contributor may be the use of sulfonylurea drugs, the most widely used oral hypoglycemic agents. Such a possibility, which first arose over a 25 years ago when it was observed that patients taking sulfonylurea drugs had increased cardiovascular mortality, has recently resurfaced after the discovery that sulfonylureas act by inhibiting adenosine triphosphate (ATP)-sensitive potassium channels. In the pancreas, inhibition of ATP-sensitive potassium channels induces release of insulin; but in the heart, inhibition of these channels prevents ischemic preconditioning, an endogenous cardioprotective mechanism that protects the heart from lethal injury. This review outlines the current understanding of the molecular and cellular pharmacodynamics of sulfonylurea drugs and discusses the potential clinical consequences of inhibition of ATP-sensitive potassium channels in the heart of diabetic patients with cardiac disease in whom the use of sulfonylureas may be harmful.

This article has been cited by other articles:

				N. Misaki, X. Mao, Y.-F. Lin, S. Suga, G.-H. Li, Q. Liu, Y. Chang, H. Wang, M. Wakui, and J. Wu Iptakalim, a Vascular ATP-Sensitive Potassium (KATP) Channel Opener, Closes Rat Pancreatic beta-Cell KATP Channels and Increases Insulin Release J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 871 - 878. [Abstract] [Full Text] [PDF]

				S. Yamada, G. C. Kane, A. Behfar, X.-K. Liu, R. B. Dyer, R. S. Faustino, T. Miki, S. Seino, and A. Terzic Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant J. Physiol., December 15, 2006; 577(3): 1053 - 1065. [Abstract] [Full Text] [PDF]

				X.-K. Liu, S. Yamada, G. C. Kane, A. E. Alekseev, D. M. Hodgson, F. O'Cochlain, A. Jahangir, T. Miki, S. Seino, and A. Terzic Genetic Disruption of Kir6.2, the Pore-Forming Subunit of ATP-Sensitive K+ Channel, Predisposes to Catecholamine-Induced Ventricular Dysrhythmia Diabetes, December 1, 2004; 53(suppl_3): S165 - S168. [Abstract] [Full Text] [PDF]

				M. Zaugg, M. C. Schaub, and P. Foex Myocardial injury and its prevention in the perioperative setting Br. J. Anaesth., July 1, 2004; 93(1): 21 - 33. [Abstract] [Full Text] [PDF]

				J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon Pharmacology of cardiac potassium channels Cardiovasc Res, April 1, 2004; 62(1): 9 - 33. [Abstract] [Full Text] [PDF]

				S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch Management of Diabetes and Hyperglycemia in Hospitals Diabetes Care, February 1, 2004; 27(2): 553 - 591. [Full Text] [PDF]

				J J Meier, B Gallwitz, W E Schmidt, A Mugge, and M A Nauck Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart, January 1, 2004; 90(1): 9 - 12. [Abstract] [Full Text] [PDF]

				J. F. Huizar, L. A. Gonzalez, J. Alderman, and H. S. Smith Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1017 - 1021. [Abstract] [Full Text] [PDF]

				P. A. Brady and A. Jovanovic The sulfonylurea controversy: Much ado about nothing or cause for concern? J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1022 - 1025. [Full Text] [PDF]

				A. Munoz, M. Nakazaki, J. C. Goodman, R. Barrios, C. G. Onetti, J. Bryan, and L. Aguilar-Bryan Ischemic Preconditioning in the Hippocampus of a Knockout Mouse Lacking SUR1-Based KATP Channels Stroke, January 1, 2003; 34(1): 164 - 170. [Abstract] [Full Text] [PDF]

				P. R. Moreno, A. M. Murcia, I. F. Palacios, M. N. Leon, V. H. Bernardi, V. Fuster, and J. T. Fallon Coronary Composition and Macrophage Infiltration in Atherectomy Specimens From Patients With Diabetes Mellitus Circulation, October 31, 2000; 102(18): 2180 - 2184. [Abstract] [Full Text] [PDF]

				D.J. Betteridge and L. Close Diabetes, coronary heart disease and sulphonylureas--not the final word Eur. Heart J., May 2, 2000; 21(10): 790 - 792. [PDF]

				D. L. Bhatt, S. P. Marso, A. M. Lincoff, K. E. Wolski, S. G. Ellis, and E. J. Topol Abciximab reduces mortality in diabetics following percutaneous coronary intervention J. Am. Coll. Cardiol., March 15, 2000; 35(4): 922 - 928. [Abstract] [Full Text] [PDF]

				K.-H. Mak and E. J. Topol Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus J. Am. Coll. Cardiol., March 1, 2000; 35(3): 563 - 568. [Abstract] [Full Text] [PDF]

				K. N. Garratt Reply J. Am. Coll. Cardiol., March 1, 2000; 35(3): 820 - 820. [Full Text] [PDF]

				A Klamann, P Sarfert, V Launhardt, G Schulte, W.H Schmiegel, and M.A Nauck Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide) Eur. Heart J., February 1, 2000; 21(3): 220 - 229. [Abstract] [PDF]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				M. R. ABRAHAM, A. JAHANGIR, A. E. ALEKSEEV, and A. TERZIC Channelopathies of inwardly rectifying potassium channels FASEB J, November 1, 1999; 13(14): 1901 - 1910. [Abstract] [Full Text]

				K. N. Garratt, P. A. Brady, N. L. Hassinger, D. E. Grill, A. Terzic, and D. R. Holmes Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction J. Am. Coll. Cardiol., January 1, 1999; 33(1): 119 - 124. [Abstract] [Full Text] [PDF]